VLGC Virologic (MM)

ViroLogic Announces Presentations on Its eTag Technology at the 2005 American Society of Clinical Oncology Annual Meeting (ASCO) SOUTH SAN FRANCISCO, Calif., May 4 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (NASDAQ:VLGC) announced today multiple presentations and publications related to its eTag(TM) technology. The presentations and publications are part of the proceedings at the 2005 American Society of Clinical Oncology Annual Meeting (ASCO) being held May 13-17, 2005 at the Orange County Convention Center in Orlando, FL. ViroLogic scientists will make the following presentations: Sunday, May 15, 2005 Session: Tumor Biology and Human Genetics Title: Analysis of ErbB/HER Receptor Pathways in Formalin-fixed and Paraffin-embedded Cancer Cell Lines using Multiplexed eTag Assays Abstract #9565: 8:00 a.m. - 12:00 p.m. Session: Tumor Biology and Human Genetics Title: Detection of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Homodimers, Phosphorylation and Downstream Pathway Activation in Endothelial Cells using eTag Assay System Abstract #9595: 8:00 a.m. - 12:00 p.m. Monday, May 16, 2005 Session: Breast Cancer Title: ErbB/HER Pathway Profiling in Formalin-fixed Paraffin-embedded Tissues using Multiplexed Proximity-based Assays Abstract #645: 2:00 - 6:00 p.m. Session: Breast Cancer Title: ErbB/Her Dimerization in Breast and Lung Cancer Abstract #643: 2:00 - 6:00 p.m. Tuesday, May 17, 2005 Session: Breast Cancer II Title: The use of ErbB/HER Activation Status as Prognostic Markers in Breast Cancer Patients Treated with Trastuzumab (Herceptin(R)) Abstract #553: 8:00 a.m. - 12:00 p.m. Poster Discussion eTAG Published Abstracts Abstract #9618 Title: Predictive Value of eTag Dimerization Assay in Patients with Metastatic Colorectal Cancer Treated with Erlotinib (Tarceva(R)) Abstract #808 Title: ErbB/Her Dimerization Profiles and Targeted Therapy in Breast and Lung Cancer Abstract #3172 Title: Effect of Gefitinib (Iressa(R)) on EGFR Mutated Lung Cancer Cell Lines About the eTag System ViroLogic's eTag assays enable detailed analysis of protein drug targets and signaling pathways in cancer cells, including samples that are formalin-fixed, paraffin-embedded, which is the standard format in most pathology labs. The assays can provide information on a drug's mechanism of action, selectivity and potency in a biological setting in pre-clinical research, and enable enrichment or selection of clinical trial populations later in a drug's development. In addition, ViroLogic believes these assays will be used to help physicians better determine whether certain therapies are more appropriate for individual cancer patients, and whether to combine therapies with different mechanisms or properties. About ViroLogic ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.virologic.com/. NOTE: eTag is a trademark of ViroLogic, Inc. Herceptin(R) and Tarceva(R) are registered trademarks of Genentech. Iressa(R) is a registered trademark of AstraZeneca. DATASOURCE: ViroLogic, Inc. CONTACT: Alfred Merriweather, Vice President and CFO of ViroLogic, +1-650-635-1100; or Carolyn Bumgardner Wang of WeissComm Partners, +1-415-946-1065, or , for ViroLogic Web site: http://www.virologic.com/

Copyright